GCCL Advances Its Role in Clinical Trials at Asia Bio Partnering Forum 2026

GCCL, or Global Clinical Central Lab, a prominent South Korean provider specializing in clinical trial sample analysis, has recently enhanced its footprint in the Asia-Pacific region. The company actively participated as a Platinum Sponsor at the prestigious Asia Bio Partnering Forum 2026 (ABP 2026), which took place in Singapore from August 31 to September 2.

The ABP 2026 event attracted attention from industry professionals, featuring a myriad of partnering meetings among global pharmaceutical and biotechnology firms, contract research organizations (CROs), and regional stakeholders. This strategic engagement allowed GCCL to explore new avenues for expanding its clinical sample analysis and assay development services across Asia.

During the forum, GCCL representatives interacted with drug developers focusing on various therapeutic modalities, including mRNA and nucleic acid therapeutics, radiopharmaceuticals, and antibody-based therapies. The discussions centered around evolving analytical requirements that play a crucial role in global clinical development, alongside potential partnerships for future collaboration.

GCCL's engagement was further bolstered by meetings with executives from global CROs and Singaporean pharmaceutical, diagnostics, and clinical trial service organizations. These conversations aimed to review existing partnerships and evaluate opportunities for deeper collaboration. Moreover, GCCL explored potential support systems for local biotech companies, engaging with a Singapore government-affiliated economic development organization to fortify connections within the local life sciences ecosystem.

As a prominent sponsor, GCCL also hosted the official ABP 2026 Welcome Reception, where Yoo-Hwa Choi, the Head of Business Operations at GCCL, delivered welcome remarks highlighting the company’s capabilities in clinical sample analysis and commitment to aiding global drug development initiatives.

At their dedicated exhibition booth, GCCL showcased an integrated approach that combines Central Lab, Bioanalytical Lab, and Research and Development Lab services. This comprehensive suite of capabilities supports clinical development from early to late-stage trials, demonstrating GCCL’s commitment to providing robust solutions tailored to the needs of pharmaceutical and biotechnology companies across Korea, China, Japan, Singapore, Vietnam, and Europe.

Yoo-Hwa Choi stated, "ABP 2026 provided an important opportunity to engage directly with drug developers and global partners across the Asia-Pacific region and better understand their evolving analytical needs across increasingly diverse therapeutic modalities. We will continue to build on these relationships and expand collaboration with global CROs and regional biotech companies as we strengthen GCCL's role as a trusted clinical development partner in Asia-Pacific."

The Asia Bio Partnering Forum gathered approximately 650 professionals from the pharmaceutical and biotechnology industries, investors, and life sciences stakeholders, culminating in around 2,500 one-on-one partnering meetings throughout the event.

About GCCL

GCCL operates as a subsidiary of the GC Group, established as a leading provider of clinical trial sample analysis. The company offers an integrated "one-stop lab solution" comprising central, bioanalysis, and biosafety level 3 laboratories, all functioning under a unified system. With customized solutions, GCCL provides precise and effective analytical services across all phases of clinical trials, reinforcing its position as a reliable partner in new drug development. Recent accolades, such as Frost & Sullivan's 2025 Best Practices Customer Value Leadership Award in the Asia-Pacific clinical sample analysis sector, underline GCCL’s pivotal role in this domain. For further information, visit www.eng.gccl.co.kr.